176,859 startups read our weekly essays.

nfx-brand-symbols

Why C2i is the World’s First Platform for Cancer Intelligence

Omri Amirav-Drory, Ph.D. · @omri_drory · Apr 2022

The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.

C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.

Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.

Asaf and Omri’s conversation begins at 11:15

Visit C2i to learn more – https://c2i-genomics.com/


nfx-brand-symbols
Stay up to speed
Weekly resources, news, and stories. Be the first to know and get insider tips.
176,859 startups read our weekly essays.
Profile picture of Omri Amirav-Drory, Ph.D.
Omri Amirav-Drory, Ph.D.
2-time scientist-founder. Founder at Genome Compiler, founding CEO of Tech.bio. Head of NFX Bio.
Tel Aviv/Menlo Park
Author
Connect with
Omri Amirav-Drory, Ph.D.

As Founders ourselves, we respect your time. That’s why we built BriefLink, a new software tool that minimizes the upfront time of getting the VC meeting.

Simply tell us about your company in 9 easy questions, and you’ll hear from us if it’s a fit.

Tell Omri Amirav-Drory, Ph.D. about your company